This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Myriad To Present New Molecular Data For Patients With Prostate Cancer At The American Urological Association 2013 Annual Meeting

SALT LAKE CITY, May 2, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today highlighted new clinical data on the PROLARIS 46-gene cell cycle progression (CCP) signature in patients with prostate cancer that will be presented at this year's American Urological Association (AUA) in San Diego.

"We have realized for some time that current clinical-pathologic features, while informative, are still inadequate in determining prostate cancer aggressiveness for an individual," said Michael Brawer, vice president of Medical Affairs at Myriad. "Every corner of the healthcare system including providers, payors, patients and health policy experts are asking for a test that can better determine prostate cancer aggressiveness and give more precise guidance of management options."

The clinical studies being presented at AUA focus on PROLARIS test results in patients who underwent radical prostatectomy or who were treated with external beam radiation therapy. In both of these prospectively-designed studies, the PROLARIS signature consistently demonstrated additional prognostic utility beyond what is available from standard clinical parameters such as Gleason score, prostate specific antigen (PSA) level and clinical stage. 

"The PROLARIS signature is the dominant variable at diagnosis in predicting risk of prostate cancer progression, as determined by the gold standard oncologic endpoints such as biochemical recurrence, metastasis and prostate cancer death," said Brawer. "The PROLARIS score can provide personalized risk of cancer progression above that afforded by the Gleason score, clinical stage and PSA level. This information can help clinicians identify patients who are good candidates for conservative management and patients for whom monotherapy with surgery or radiation therapy may be inadequate."

These findings complement clinical data previously published in the peer-reviewed scientific literature. Myriad's PROLARIS test is the only commercial product that predicts prostate cancer death and has been evaluated in nine clinical studies with more than 3,000 patients. PROLARIS also is the only product that can be used in multiple sample types giving it applicability in both pre-treatment biopsy specimens and radical prostatectomy samples.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.02 0.00%
FB $104.07 0.00%
GOOG $683.57 0.00%
TSLA $162.60 0.00%
YHOO $27.97 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs